Comparative Analysis of White Matter Signal Alterations in Dementia With Lewy Bodies and Alzheimer's Disease: A Systematic Review and Meta-Analysis Publisher



Abdi A^{1, 2} ; Alipour M³ ; Ghanikolahloo M⁴ ; Magsudy A⁵ ; Hojjatipour F⁶ ; Gholamrezanezhad A^{7, 8} ; Ilaghi M⁹ ; Anjomrooz M¹⁰ ; Sayehmiri F¹¹ ; Hajibeygi R^{12, 13} ; Fathi M⁶ ; Assadsangabi R⁷
Source: Frontiers in Radiology Published:2025

Abstract

Background and aim: Lewy body diseases (LBD) include neurodegenerative diseases such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), and Parkinson's disease dementia (PDD). Because DLB and Alzheimer's disease (AD) share similar neurological symptoms, DLB is frequently underdiagnosed. White Matter Hyperintensities (WMH) are associated with dementia risk and changes in both DLB and AD. In order to examine WMH discrepancies in DLB and AD patients and gain insight into their diagnostic utility and pathophysiological significance, this systematic review and meta-analysis is conducted. Material and methods: Databases such as PubMed, Scopus, Google Scholar, and Web of Science were searched for studies reporting WMH in DLB and AD patients based on Preferred Reporting Items for Systematic Review (PRISMA) guideline. Stata version 15 US is used to analyze the extracted data. Results: Twelve studies with 906 AD and 499 DLB patients were considered in this analysis. Although not statistically significant, the WMH was 0.03 ml larger in AD patients than in DLB patients. The prevalence of hypertension varied, ranging from 21% to 56% in DLB patients and from 30% to 52% in AD patients. Different findings were found on the prevalence of diabetes; some research suggested that DLB patients had greater rates (18.7%–37%) than AD patients (9%–17.5%). The imaging modalities FLAIR, T2-weighted, and T1-weighted sequences were employed. Compared to DLB patients, AD patients had higher cortical and infratentorial infarcts. Conclusion: Those with AD have greater WMH volumes than cases with DLB, suggesting that WMH can be a biomarker to help better differentiation between these neurodegenerative diseases; however, this difference is not significant. To better understand the therapeutic implications and options for reducing WMH-related cognitive loss in various patient populations, more research is necessary. 2025 Abdi, Alipour, Ghanikolahloo, Magsudy, HojjatiPour, Gholamrezanezhad, Ilaghi, Anjomrooz, Sayehmiri, Hajibeygi, Fathi and Assadsangabi.